EHC vs UNH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

UNH is the larger of the two ($357.88B market cap): the incumbent the market prices for continued execution (17.12x forward earnings, beta 0.52). EHC is the smaller challenger ($13.89B), actually pricier on forward earnings (20.55x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

EHC vs UNH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricEHCUNHWhat it tells you
Market cap$13.89B$357.88BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E20.5517.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E22.6522.80Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.670.52Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range96% of range70% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.193.65How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: UNH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how EHC and UNH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EHC and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EHC and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Encompass Health (EHC) do?

Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. As of the second quarter of 2026 it operated 176 hospitals (about 178 by October 2026) across 39 states and Puerto Rico, which makes it the largest operator in the category by a wide margin. Medicare fee-for-service is its dominant payer, and under the IRF prospective payment system it is paid a set amount per discharge based on the patient's condition and complexity, so revenue is essentially discharges multiplied by net revenue per discharge. A portion of its hospitals are structured as joint ventures with acute-care health systems, which brings referral flow and shared construction capital while handing a slice of consolidated profit to noncontrolling interests. The company became a pure-play rehabilitation operator in 2022 when it spun off its home health and hospice arm as Enhabit.

Full EHC guide

What does UnitedHealth Group (UNH) do?

UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.

Full UNH guide

EHC vs UNH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • EHC drivers: De novo hospitals and bed additions; Demographics against a supply-constrained niche.
  • UNH drivers: Optum growth engine; Medicare Advantage scale.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.

EHC or UNH: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EHC if you believe its drivers more; UNH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EHC and UNH guides.

EHC vs UNH: the full fundamentals

EHC. As of October 16, 2026 the shares traded near $128, giving a market capitalization around $12.6 billion against trailing revenue of roughly $6.21 billion. Guided 2026 adjusted EPS of $6.02 to $6.25 puts the stock at about 21 times the midpoint and about 19 times the 2027 consensus of $6.68, a premium to most hospital operators and a reflection of the visible bed pipeline rather than of any margin inflection. The stock has risen about 14 percent in three months to near a 52-week high, so the October 28 report arrives with less valuation cushion than in August.

UNH. The trailing P/E of about 26x is inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 17x, closer to its historical range. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. The stock has recovered a large part of its 2025 decline, which leaves less of a discount for regulatory and cost risk than a year ago.

Headline figures (approximate, October 2026): EHC shows revenue (ttm) ~$6.21B, q2 2026 revenue ~$1.60B, up ~9.6%, q2 2026 adjusted eps ~$1.55 (est. ~$1.48), net income (ttm) ~$604M (~10% margin); UNH shows revenue (ttm) ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year, operating margin ~5.8% (net margin ~3.5%), net income (ttm) ~$15.9 billion (sensitive to medical costs), eps ~$15.55 trailing; Q3 2026 $4.69 vs $4.14 consensus.

The bottom line: EHC vs UNH

EHC and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EHC and UNH exposure against your real portfolio. It is not an investment adviser.

Wondering how EHC or UNH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Encompass Health

Ask Walnut's AI anything about EHC and see how it fits what you own.

FAQ

What is the difference between EHC and UNH?

+

Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is EHC or UNH the better stock?

+

Neither is universally better. UNH is the larger incumbent; EHC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, EHC or UNH?

+

On forward P/E (as of November 2026), EHC trades at 20.55x and UNH at 17.12x, so UNH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both EHC and UNH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of EHC vs UNH?

+

EHC: Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026. Finally, the balance sheet carries about $2.84 billion of debt against little cash, and capital spending on new hospitals kept trailing free cash flow to about $230 million on $1.21 billion of operating cash flow, so the build-out depends on continued access to financing. UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. The 2026 recovery also raises the bar: at roughly 17x forward earnings the stock now prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EHC or UNH; figures are approximate and dated (as of November 2026). Verify current data before investing.